WICHITA, Kan. (KSNW) – Doctors say thunderstorms can trigger something dangerous for people with asthma. It’s called “thunderstorm asthma,” and new research shows emergency rooms can see a spike in ...

Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly ...

A pulmonologist discusses the history and influence of race-based reference equations in pulmonary function testing interpretation and patient care.

New York City’s Mold Busters program is associated with thousands fewer emergency department visits for asthma per year, ...

The European Commission on Tuesday approved GSK plc’s GSK Exdensur (depemokimab) in two indications, including: As an add-on maintenance treatment for severe asthma with type 2 inflammation, ...

– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also ...

Objective To examine the overall incidence rate and trends in emergency department (ED) presentations related to asthma and allergic diseases in regional Australia with a particular focus on First ...

Spiro Medical, which debuted last year, reeled in $67 million in series A funding it plans to use to develop its novel treatment for asthma. Dubbed the Pulmonary Neuromodulation System, the platform ...

The number of people seeking help related to a respiratory illness in Virginia spiked to nearly 25 percent of emergency room visits. Data from the Virginia Department of Health shows the illness level ...

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as an add-on maintenance treatment of severe asthma with an eosinophilic ...

(Alliance News) - GSK PLC on Wednesday said its Exdensur treatment, depemokimab, for severe asthma has been approved by the US Food & Drug Administration. The regulatory approval is based upon phase ...